Number 3: The denosumab biosimilar market is poised for disruption with 3 FDA-approved biosimilars, at least 5 awaiting approval, and launches anticipated to start in May 2025, while ongoing patent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback